CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer by the targeted killing of cancer stem cells,
announced that it will ring the Closing Bell at the NASDAQ MarketSite in
Times Square, New York City, on Thursday, July 10, 2014, at 4:00 p.m. ET.
The Closing Bell ceremony will take place immediately following the
conclusion of the Company’s annual Research and Development Day. A live
webcast of the NASDAQ Closing Bell will be available starting at 3:45
p.m. ET at http://new.livestream.com/nasdaq/live.
Verastem’s annual Research and Development Day is being held
at the Hudson Theatre at the Millennium Broadway Hotel beginning at 12:30
p.m. ET. The Company will provide updates regarding the status of
its research and development efforts, anticipated clinical milestones
and upcoming plans for its programs targeting cancer stem cells. To
attend, please RSVP to email@example.com.
Date:Thursday, July 10, 2014
Time:12:30 p.m. – 4:00 p.m.
Location:The Hudson Theatre at the Millennium Broadway
Hotel, 145 West 44th Street, New York, NY
A replay of the webcast will be archived for 90 days following the
Conference Call Dial-in (U.S.): 866-906-7447
Conference Call Dial-in (International): 617-939-0999
Conference Call Passcode: 5946305
Replay Dial-in (U.S.): 888-799-6166
Replay Dial-in (International): 857-288-2550
Replay Passcode: 5946305
The invitation can be accessed here: VSTM
R&D Day Invitation
**Lunch will be served**
About Verastem, Inc.Verastem, Inc.
(NASDAQ:VSTM) is discovering and developing drugs to
treat cancer by the targeted killing of cancer stem cells. Cancer stem
cells are an underlying cause of tumor recurrence and metastasis.
is developing small molecule inhibitors of signaling pathways
that are critical to cancer stem cell survival and proliferation: FAK,
PI3K/mTOR and Wnt. For more information, please visit www.verastem.com
Any statements in this press release about future expectations, plans
and prospects for the Company constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements. The Company anticipates that subsequent
events and developments will cause the Company’s views to change.
However, while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so.
Verastem, Inc.Brian Sullivan
Source: Verastem, Inc.